(2R,3R,4S,5S,6R)-2-(2,3-Bis-tetradecyloxy-propoxy)-6-hydroxymethyl-tetrahydro-pyran-3,4,5-triol | 85648-57-3

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 甘油脂
• 英文名称: (2R,3R,4S,5S,6R)-2-(2,3-Bis-tetradecyloxy-propoxy)-6-hydroxymethyl-tetrahydro-pyran-3,4,5-triol
• 英文别名: (2R,3R,4S,5S,6R)-2-[2,3-di(tetradecoxy)propoxy]-6-(hydroxymethyl)oxane-3,4,5-triol
• CAS: 85648-57-3
• 化学式: C₃₇H₇₄O₈
• 分子量: 646.99
• InChiKey: JTIZQTMERNEAIM-GICYAKJESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  11.1
• 重原子数：
  45
• 可旋转键数：
  33
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  118
• 氢给体数：
  4
• 氢受体数：
  8

反应信息

• 作为产物：
  描述：

  2,3,4,6-四乙酰氧基-alpha-D-吡喃葡萄糖溴化物 在 碘 、 sodium methylate 、 silver(l) oxide 作用下， 以 甲醇 、 苯 为溶剂， 反应 22.0h， 生成 (2R,3R,4S,5S,6R)-2-(2,3-Bis-tetradecyloxy-propoxy)-6-hydroxymethyl-tetrahydro-pyran-3,4,5-triol
  参考文献：
  名称：

  An efficient and stereoselective synthesis of 1,2-0-dialkyl-3-0-β-d-dlycosyl-sn-glycerols

  摘要：

  DOI：

  10.1016/s0040-4039(00)81621-4

文献信息

• Enzymatic activity assays for glucocerebrosidase
  申请人：Shire Human Genetic Therapies, Inc.

  公开号：US10760112B2

  公开（公告）日：2020-09-01

  The present invention provides, among other things, methods and compositions for determining enzyme kinetic parameters (e.g., Vmax, Km, and specific activity, etc.) indicative of clinically relevant properties of glucocerebrosidase using a physiologically relevant substrate, in particular, a substrate that is representative of substrates that typically accumulate in patients suffering from Gaucher disease such as glucosylceramide. Thus, the present invention is particularly useful to measure a kinetic parameter relating to the activity of glucocerebrosidase in a drug substance, drug product, and stability sample for enzyme replacement therapy.

  本发明除其他外，提供了使用生理相关底物，特别是使用代表通常在戈谢病患者体内蓄积的底物（如葡萄糖甘油酰胺）来确定指示葡萄糖脑苷脂酶临床相关特性的酶动力学参数（如Vmax、Km和比活性等）的方法和组合物。因此，本发明特别适用于测量酶替代疗法的药物物质、药物产品和稳定性样品中与葡萄糖脑苷脂酶活性有关的动力学参数。
• ENZYMATIC ACTIVITY ASSAYS FOR GLUCOCEREBROSIDASE
  申请人：Shire Human Genetic Therapies, Inc.

  公开号：US20180051315A1

  公开（公告）日：2018-02-22

  The present invention provides, among other things, methods and compositions for determining enzyme kinetic parameters (e.g., Vmax, Km, and specific activity, etc.) indicative of clinically relevant properties of glucocerebrosidase using a physiologically relevant substrate, in particular, a substrate that is representative of substrates that typically accumulate in patients suffering from Gaucher disease such as glucosylceramide. Thus, the present invention is particularly useful to measure a kinetic parameter relating to the activity of glucocerebrosidase in a drug substance, drug product, and stability sample for enzyme replacement therapy.